CervoMed Inc.

CervoMed Inc. is a clinical-stage biotechnology company dedicated to developing treatments for age-related neurologic disorders, particularly neurodegenerative diseases. The company's mission is to advance central nervous system (CNS)-focused therapeutics to benefit patients suffering from a range of debilitating conditions, with a core belief in early intervention by targeting synaptic dysfunction. CervoMed's headquarters are located in Boston, Massachusetts.

The company's lead product candidate is neflamapimod, an investigational, orally administered small molecule brain penetrant. Neflamapimod works by inhibiting p38MAP kinase alpha (p38α), an enzyme believed to drive inflammation-induced synaptic toxicity and dysfunction in neurons. This mechanism aims to reverse synaptic dysfunction, improve neuron health, and potentially slow or prevent disease progression. CervoMed is primarily focused on the clinical development of neflamapimod for Dementia with Lewy Bodies (DLB) and is also exploring its potential for non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, frontotemporal dementia, and stroke recovery.

CervoMed has reported positive 16-week results from the extension phase of its Phase 2b RewinD-LB trial for neflamapimod in DLB, demonstrating improvements on the primary outcome measure, and plans to initiate a Phase 3 trial in mid-2026. The company was also awarded the 2024 Prix Galien USA Award as “Best Startup.” Led by CEO and co-founder John Alam, MD, CervoMed positions itself as a leader in the DLB treatment landscape, with neflamapimod being the only clinical drug candidate to show statistically significant improvements in Phase 2a and positive outcomes in Phase 2b, specifically targeting DLB patients without Alzheimer's disease co-pathology.